Meeting
2015 ASCO Annual Meeting
Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies.
Authors
Andrew Eugene Hendifar
Cedars-Sinai Medical Center, Los Angeles, CA
Andrew Eugene Hendifar , Neal S Chawla , Kamalesh Kumar Sankhala , Xiao Zhang , Doris V. Quon , Victoria S Chua , Lita Fernandez , William E. Mendanha , Sant P. Chawla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 33, 2015 (suppl; abstr 10573)
DOI
10.1200/jco.2015.33.15_suppl.10573
Abstract #
10573
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2022 ASCO Annual Meeting
A phase II study of gemcitabine docetaxel combination in metastatic/unresectable locally advanced relapsed synovial sarcoma.
First Author: Ghazal Tansir
Poster
2014 ASCO Annual Meeting
Low-dose gemcitabine doxorubicin and docetaxel combination in patients with advanced/unresectable/metastatic sarcoma who failed prior chemotherapy: Updated analysis.
First Author: Vivek Narasimhan
Poster
2023 ASCO Annual Meeting
Results of SOC-2082 phase 2 study using metronomic gemcitabine, doxorubicin and docetaxel plus nivolumab as second/third-line therapy for advanced sarcoma.
First Author: Nadezhda Omelchenko